Trial Profile
A Retrospective Study of Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer in Greece (The "RESPONSE" Study).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2012
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms RESPONSE
- 12 Mar 2012 Actual end date Sep 2011 added as reported by ClinicalTrials.gov.
- 12 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jul 2011 New trial record